The FemTech Ghetto and the Niche Trap

Transcript

A startup develops an at-home cervical screening tool, a potential life-saver by catching cancer early. Yet, investors suggest pivoting to beauty wellness, deeming the cancer product too slow and complex. This scenario isn't hypothetical. A European FemTech founder faced this exact situation, highlighting how investment decisions often reflect values rather than market potential, categorizing women's health as secondary. We traced the funding gap upstream to the capital sources that shape what VC firms prioritize. Now the question is: what happens inside that system to the specific products women need most? The answer has a name. Founders call it the FemTech ghetto. Here's how the trap works. An investor sees a pitch for a menopause diagnostic. The first question isn't about the science. It's about market size. According to the Financial Times in May 2026, European FemTech founders said investors routinely described women's health products as a nice-to-have and questioned total addressable market. Think of it this way: half the global population experiences menopause. That is not a niche. The Financial Times also reported that some VC partners privately acknowledge using informal filters that deprioritize decks featuring explicit discussions of menstruation or menopause — topics considered uncomfortable for mostly male investment committees. The market is enormous. The discomfort is the filter. Reuters reported in May 2026 that PitchBook data showed global venture funding for women's health rose year-on-year — but still represented a small single-digit percentage of overall digital health investment. The New York Times reported in May 2026 that some prominent generalist VC firms ran internal diversity dashboards and discovered their portfolios had less than two percent allocation to FemTech. Partners were shocked. They believed they were already supporting the space. Bloomberg reported in May 2026 that even dedicated women's health funds remain tiny compared with generalist health or AI megafunds. And the New York Times noted that while large health systems integrate AI for cardiology and oncology, many FemTech products stay confined to consumer wellness apps — far from reimbursable clinical care. The ghetto has an inner ring. The Guardian reported in May 2026 that Black and Latina FemTech founders in the United States face compounded barriers — investors view women's health as niche and question the relevance of products tailored to women of color. That is a narrower funnel inside an already narrow funnel. AP News reported in May 2026 that post-Roe regulatory uncertainty has made some investors more cautious about reproductive-health deals, deepening the financial ghetto around abortion, contraception, and pregnancy loss care. The BBC reported that founders building AI diagnostics for endometriosis are steered toward fertility tracking instead — perceived as more monetizable. [short pause] And AP News reported that large language models used in symptom checkers performed significantly worse when trained on male-dominated clinical datasets. The bias isn't just in the pitch room, Julie. It's encoded in the tools. The niche label is a perception, not a market reality, shaped by the biases of investment committees. Founders are countering biases by rebranding, dropping the FemTech label, and positioning as AI or data infrastructure firms, which has significantly improved fundraising outcomes. Deutsche Welle reported that a European coalition launched clinical-validation benchmarks to reposition women's health apps as clinically indispensable. The BBC also reported that European pension funds are beginning to include women's health outcomes in ESG mandates, pressuring VC firms to justify underweight allocations. And the New York Times reported that major U.S. employers are adding menopause and fertility benefits to health plans, opening B2B revenue channels that pull FemTech out of the consumer-app corner. Here's the takeaway: when investors call women's health niche, they are not describing the market. They are describing their own blind spot.